123 related articles for article (PubMed ID: 37981702)
1. Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
Yang L; Lu X; Luo J; Huang D; Dai X; Yang Y; Dai N; Xiong Y
Am J Clin Oncol; 2024 Mar; 47(3):115-121. PubMed ID: 37981702
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Hu X; Bao Y; Chen YY; Gao JM; Wang WH; Liu Y; He H; Sun ZW; Poudel S; Wang Y; Zhuang TT; Zhang L; Chen M
Ai Zheng; 2008 Oct; 27(10):1088-93. PubMed ID: 18851790
[TBL] [Abstract][Full Text] [Related]
3. Curative effect of hyperfractionated accelerated radiotherapy combined with EP chemotherapy regimen on limited-stage small cell lung cancer.
Tan Y; Zhu QYXWH
J BUON; 2021; 26(3):837-843. PubMed ID: 34268943
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
Li C; Xiong Y; Zhou Z; Peng Y; Huang H; Xu M; Kang H; Peng B; Wang D; Yang X
Med Oncol; 2014 Dec; 31(12):369. PubMed ID: 25416052
[TBL] [Abstract][Full Text] [Related]
5. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
14. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
15. Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
Viani GA; Gouveia AG; Matsuura FK; Jacinto AA; Moraes FY
Radiother Oncol; 2022 Aug; 173():41-48. PubMed ID: 35101470
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
Han J; Fu C; Li B
Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
[TBL] [Abstract][Full Text] [Related]
17. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
18. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
Suzuki R; Wei X; Allen PK; Welsh JW; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2018 Nov; 19(6):e885-e891. PubMed ID: 30197263
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
[TBL] [Abstract][Full Text] [Related]
20. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]